Skip to main content

Advertisement

SpringerLink
Log in

Does addition of lapatinib to capecitabine improve outcome in women with refractory breast cancer?

  • Practice Point
  • Published:

From Nature Clinical Practice Oncology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Slamon DJ et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792

    Article  CAS  Google Scholar 

  2. Valabrega G et al. (2007) Trastuzumab: mechanism of action, resistance and future perspectives in HER2 overexpressing breast cancer. Ann Oncol [doi: 10.1093/annonc/mdl475]

  3. Montemurro F et al. (2006) Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist 11: 318–324

    Article  CAS  Google Scholar 

  4. Gomez HL et al. (2006) Updated biomarker results from a phase II randomized study of lapatinib as first-line treatment for patients with ErbB2-amplified advanced or metastatic breast cancer [abstract #1090]. Breast Cancer Res Treat 100 (Suppl): S68

    Google Scholar 

  5. Xia W et al. (2007) Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res 67: 1170–1175

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. F Montemurro is a Medical Oncologist of the University Division of Medical Oncology and Haematology Institute for Cancer Research and Treatment (IRCC), Candiolo, Torino, Italy.,

    Filippo Montemurro

  2. M Aglietta is Head of the University Division of Medical Oncology and Haematology Institute for Cancer Research and Treatment (IRCC), Candiolo, Torino, Italy. M Aglietta is also a Full Professor of Oncology at the University of Turin, Italy.,

    Massimo Aglietta

Authors
  1. Filippo Montemurro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Massimo Aglietta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Filippo Montemurro.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Montemurro, F., Aglietta, M. Does addition of lapatinib to capecitabine improve outcome in women with refractory breast cancer?. Nat Rev Clin Oncol 4, 398–399 (2007). https://doi.org/10.1038/ncponc0849

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0849

  • Springer Nature Limited

This article is cited by

Search

Navigation